Results 31 to 40 of about 9,892 (240)

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care [PDF]

, 2017
Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterised by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations.
Alastair Kent, Albert C M Ong, Brenda de Coninck, Denis Clément, Dorien Peters, Elena Levtchenko, Hendrik Van Poppel, Joost P H Drenth, José Luis Górriz, Klemens Budde, Lorenzo E Derchi, Marianna Eleftheroudi, null null, null null, null null, Olivier Devuyst, Raymond Vanholder, Richard Sandford, Ron T Gansevoort, Tess Harris, Tevfik Ecder, Vicente E Torres, Yves Pirson   +22 more
core   +6 more sources

Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

BMC Nephrology, 2017
Background Tolvaptan slows progression of autosomal dominant polycystic kidney disease (ADPKD) by antagonizing the vasopressin-cAMP axis. Nitric oxide (NO) stimulates natriuresis and diuresis, but its role is unknown during tolvaptan treatment in ADPKD ...
Safa Al Therwani, My Emma Sofie Malmberg, Jeppe Bakkestroem Rosenbaek, Jesper Noergaard Bech, Erling Bjerregaard Pedersen   +4 more
doaj   +1 more source

Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan

Kidney Medicine, 2020
Rationale & Objective: Euvolemic hyponatremia often occurs due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vasopressin 2 receptor antagonists may be used to treat SIADH.
Ramy M. Hanna, Juan Carlos Velez, Anjay Rastogi, Minhtri K. Nguyen, Mohammad K. Kamgar, Kyaw Moe, Farid Arman, Huma Hasnain, Niloofar Nobakht, Umut Selamet, Ira Kurtz   +10 more
doaj   +1 more source

Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients

Pharmacology Research & Perspectives, 2023
The optimal starting dose of tolvaptan to effectively improve fluid retention in patients with heart failure (HF) is unknown. This study explored the factors affecting the pharmacokinetics (PKs) and pharmacodynamics of tolvaptan in patients with ...
Takahiro Kato, Yoko Yasuda, Hitomi Okamoto, Yuji Saito, Yusuke Nakano, Katsuhiko Matsuura, Masafumi Oonishi, Tetsuya Amano   +7 more
doaj   +1 more source

Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. [PDF]

, 2020
Arginine vasopressin (AVP) and its type-2 receptor (V2R) play an essential role in the regulation of salt and water homeostasis by the kidneys. V2R activation also stimulates proliferation of renal cell carcinoma (RCC) cell lines in vitro.
Calvet, James P, Dwivedi, Nidhi, Enders, Jonathan, Jamadar, Abeda, Kakade, Vijayakumar R, Neil, Maura O', Rao, Reena, Sinha, Sonali, Tao, Shixin, Thomas, Sufi M, Weiss, Robert H   +10 more
core  

Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort

Scientific Reports, 2023
Tolvaptan is the first disease-modifying drug proven to slow eGFR decline in high-risk patients with ADPKD. However, barriers from the patient perspective to its use in real-life settings have not been systemically examined in a large cohort.
Luca Calvaruso, Kevin Yau, Pedram Akbari, Fatemah Nasri, Saima Khowaja, Bill Wang, Amirreza Haghighi, Korosh Khalili, York Pei   +8 more
doaj   +1 more source

Identification and Characterization of an Activating F229V Substitution in the V2 Vasopressin Receptor in an Infant with NSIAD [PDF]

, 2012
Gain-of-function mutations in the gene encoding the V2 vasopressin receptor (V2R) cause nephrogenic syndrome of inappropriate antidiuresis. To date, reported mutations lead to the substitution of arginine 137 by either a cysteine or leucine (R137C/L ...
Abrol, Ravinder, Bichet, Daniel G., Bouvier, Michel, Carpentier, Eric, Goddard, William A., III, Greenbaum, Larry A., Rochdi, Driss   +6 more
core   +1 more source

A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

BMC Nephrology, 2022
Background Tolvaptan was approved in the United States in 2018 for patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression as assessed in a 3-year phase 3 clinical trial (TEMPO 3:4).
Gregory Mader, Deirdre Mladsi, Myrlene Sanon, Molly Purser, Christine L. Barnett, Dorothee Oberdhan, Terry Watnick, Stephen Seliger   +7 more
doaj   +1 more source

The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models [PDF]

, 2015
Desmopressin (dDAVP) is a safe haemostatic agent with previously reported antitumour activity. It acts as a selective agonist for the V2 vasopressin membrane receptor (V2r) present on tumour cells and microvasculature.
Alonso, Daniel Fernando, Garona, Juan, Gomez, Daniel Eduardo, Iannucci, Nancy Beatriz, Orlando, Ulises Daniel, Ortega, Hugo Hector, Pastrian, María Belén, Pifano, Marina, Podesta, Ernesto Jorge, Ripoll, Giselle Vanina   +9 more
core   +1 more source

Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan

Therapeutic Advances in Cardiovascular Disease, 2019
Background: Although tolvaptan, an electrolyte-free water diuretic for congestive heart failure (HF), is reported to have no effect on long-term mortality or HF-related morbidity, there may exist some subgroups of patients who may receive beneficial ...
Kensuke Fujioka, Sumio Mizuno, Taro Ichise, Takao Matsui, Hiroaki Hirase, Masato Yamaguchi, Takahiko Aoyama, Masakazu Yamagishi, Noboru Fujino, Masa-aki Kawashiri, Kenshi Hayashi   +10 more
doaj   +1 more source